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Abstract— In countries with a national health service, new 
telemedicine and telehealth products and services are 
‘commissioned’ according to a fairly rigorous and regulated 
process, that usually involves pilot studies and the assembly of 
‘evidence’ to show that the innovation offers performance 
and/or cost advantages. This is problematic for several 
reasons and means that many innovations are piloted and 
performance evaluated, but relatively few pass into 
mainstream adoption. The current relationship between 
healthcare commissioners and technology developers is 
adversarial rather than collaborative. Evaluations and 
regulatory systems place the responsibility with the developer 
to prove that the solution works – in other words, to refute the 
assumption that the solution may not be appropriate. 
Furthermore, with telemedicine innovations the ‘user’ and the 
‘customer’ is not a single individual or organisation – the 
healthcare professional, the patient (and perhaps carer, family 
or friends), as well as the organisation itself are all involved. A 
conventional evaluation ignores the organisationally 
disruptive aspect of the technology. A better question than 
‘does it work?’ would be ‘how can we use it?’ This paper 
reviews barriers to adoption and considers the particular 
issues that developers of telemedicine apps need to address. 
We propose the Stakeholder Empowered Adoption (SEA) 
Model, as a process that builds stakeholder (staff and patients, 
managers, technologists) perspectives into the specification 
and early design stages and uses scenario modelling and 
simulations to avoid dependence on actual prototypes. The 
model recognises that the main economic stakeholders (the 
health organisation commissioning the innovation and the 
technology provider) need to drive the process, but end users 
(professionals and patients) are critical to a useful, adoptable 
end product. Their involvement in the evaluation and 
adoption process therefore needs to be well managed.  
Keywords – telemedicine, telehealth, technology adoption, 
co-design, self management, patient empowerment. 
I. INTRODUCTION
Growth of open software platforms, lower cost mobile 
hardware and growing consumer acceptance of technology 
has made it much easier for technology developers to 
produce healthcare self-management tools or ‘apps’ (web or 
mobile based software applications). The plethora of new 
technologies across the fields of wireless technologies, 
pharmacogenomics, cloud computing and data mining 
(amongst others) offer enormous opportunities for 
technologists to provide personalized healthcare tools [1]. 
Increasingly such tools are available on consumer devices 
and are being adopted unilaterally by individual users. 
However, within mainstream health services, particularly 
within the European nationalized services, adoption has 
been frustratingly slow. A recent qualitative evaluation of 
the UK Whole System Demonstrator project, a very large 
scale telehealth and telecare pilot involving over 6000 
patients, concluded that  a major barrier to adoption of 
telehealth is that it requires re-design of health services [2]. 
This requirement for health re-design is disruptive: it 
requires significant changes to the ways professionals 
engage with each other and with patients or carers. 
Successful adoption of telehealth almost certainly means 
close collaboration with users during the development, 
piloting and evaluation phases. A number of models have 
been developed to describe this process and provide a 
framework [3], [4]. Unlike in consumer markets, for which 
many apps are produced, healthcare ‘customers’ are a 
complex group. A decision to purchase involves not only the
direct users (doctors, nurses or other health professionals), 
but also managers (healthcare commissioners) who must 
ensure that solutions offer a level of performance that is 
commensurate with cost. In telehealth, telecare, 
telemedicine, the patient (and often friends or family) are 
also key users and may even need to provide part of the 
solution themselves (eg. a smartphone).  
In this first part of this paper, the barriers to adoption of 
telemedicine apps by mainstream healthcare commissioners 
will be reviewed, through a discussion of models for user 
engagement. This is followed by a discussion of the 
implications for technology developers and strategies to 
address the challenges. Finally, a proposed approach, the 
Stakeholder Empowered Adoption Model, is outlined.  
II. BARRIERS TO ADOPTION OF TELEMEDICINE APPS
As telemedicine apps are classed as medical devices 
(they provide diagnostic or therapeutic outputs that could 
have safety implications for the patients or other users), it is 
important that they are carefully evaluated before 
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introduction. Evidence must be compiled to show that the 
app fulfills its intended clinical purpose and performs better 
in terms of clinical outcomes than the conventional solution 
(sometimes called the ‘gold standard’). Healthcare 
commissioners are also required to consider economic 
factors. The new solution should either perform equally well 
at lower cost, or better at the same cost as the conventional 
solution. This approach is enshrined within international 
regulatory systems [5], which are in place to protect patients 
and the public from the very real risks of inadequately 
researched or poorly designed medical devices and drugs.  
Unlike apps developed for consumer uses, where the 
market forces are used to judge good and bad quality, 
telemedicine apps are subject to regulation. Moreover, 
consumers of health related products are conventionally 
guided by their health provider and tend to require 
validation of their purchasing decisions where medical 
products are concerned. This is even more important if they 
are receiving treatment as part of a programme and may be 
concerned about how a unilateral health management 
decision would affect their condition.  
Implementation of robust and highly procedural 
evaluations has led to the growth of a significant 
organizational structure of commissioners within health 
services, mirrored by regulatory experts and product 
champions within large medical technology companies. The 
technology provider has to bear the cost of piloting and 
evaluation (although much government support has been 
provided). 
For telemedicine apps there are a number of problems 
with the conventional approach. Firstly, for such 
innovations, the patient (or their carer) must become the 
main user, but they are not paying for the solution (although 
they may be supplying a telephone or broadband 
connection). Secondly, there may be a number of health 
professionals supporting the telemedicine service and its 
introduction will most certainly change the nature of their 
jobs. Again, they are not directly making the payment 
decision and do not have the financial or management 
information to make this decision. Thirdly, the timescales 
for piloting and evaluation may in fact be longer than the 
technology lifetime. In telemedicine, the hardware and 
software platforms are changing rapidly and may go out of 
date before commissioners are ready to make a judgment. 
There is a general recognition by policy makers that 
adoption of technology in healthcare is cumbersome, as well 
as a perception that it is slower than in other industries. 
Within the UK, a study by the King’s Fund in 2008 [6]
identified 11 factors, positive and negative, that influence 
adoption decision making. Those relevant to this discussion 
are: 
x The ability of vendors of technology to build and 
investment case and attract funding; 
x The level of engagement between technology 
suppliers and the National Health Service; 
x Consumer awareness of technology and 
understanding of the benefits it can bring. 
Paradoxically, although validation and approval of new 
technologies is controlled ‘top down’ through the regulatory 
systems (such as the Food and Drugs Administration (FDA) 
in USA and the European Medical Devices Directive 
implemented through Member States), purchasing decisions 
are fragmented and strongly influenced by local hospitals, 
commissioning groups and clinical opinion leaders. Even 
within the nationalized health services in Europe, the 
national body only provides ‘guidance’ on which 
technology should be used and which care pathway adopted.  
At the centre of the technology adoption approach,
therefore,  is an adversarial relationship between technology 
developer and healthcare commissioner. The responsibility 
lies firmly with the developer to prove that the solution 
works and provides both clinical and economic benefits. In 
fact, the regulatory system is based on an approach that the 
evaluation must refute the assumption that the solution is not 
appropriate. In the case of telemedicine, the technology is 
generally well proven in other fields, such as consumer 
markets, so the evaluation is not even asking the right 
question. The question ‘does it work?’ is irrelevant. A better 
question is ‘how can we use it?’ and also ‘how do we need 
to modify our services to use it?’
The conventional evaluation-to-adoption process for 
telemedicine apps is wasteful, costly and ultimately does not 
bring clinical benefits to patients.  
III. MODELS FOR STAKEHOLDER ENGAGEMENT IN 
DEVELOPMENT AND ADOPTION
The major difference between developing an app for a 
consumer market and for a healthcare market is that a 
consumer makes a decision to purchase as an individual. A 
healthcare commissioner must make a decision to purchase 
based on evidence from a number of stakeholders. The 
primary factors are cost and performance (efficiency and 
efficacy), geared to patient clinical outcomes. However, 
each stakeholder will weigh the factors differently, 
according to their values and beliefs.  
For a patient, their own convenience is, of course, 
critical. They may opt for a remote consultation, if the 
technology is available, because it saves them time and 
money to travel to a clinic. If they are able to make their 
own physiological measurements (blood pressure, or heart 
rate), they may be able to learn to correct their medication or 
their exercise programme directly. For the health provider, 
however, they must consider if the quality of the 
measurement is equal to that undertaken by a skilled nurse, 
or if some nuance may be missed through a telephone 
consultation because the consultant and the patient are not 
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together. The patient’s time and cost saving do not appear 
on their balance sheet, so they will naturally not rate their 
convenience so highly. The opinion of the health 
professional is more complex. Negative attitudes to 
telemedicine may be associated with job insecurity. The 
clear implication that service re-design needs to be 
associated with adoption means at the very least that some 
role changes will be made. Studies have also shown concern 
about creating a group of ‘worried well’ in which patients 
are excessively preoccupied with the symptoms and signs of 
a chronic condition [7].
In summary, findings from a pilot of a new telemedicine 
solution will be interpreted differently by each stakeholder. 
This is because each has a different set of values and beliefs, 
which act as a lens through which objective data is viewed. 
The conventional technology adoption system is designed 
around the values of the healthcare organization, but this is 
not explicitly recognized. A values-based approach to 
evaluation and adoption needs to recognize each 
stakeholder’s values explicitly and take account of the 
principle of ‘dissensus’ in which disagreement is openly 
recorded [8].
It is clear that a suitable process to aid adoption of 
telemedicine needs to take account of all the stakeholder 
perspectives and to involve users as early as possible in the 
design process. Some authors have looked at product 
development and human computer interaction (HCI) 
disciplines, for instance through the Technology Acceptance 
Model that looks at two factors for user acceptance, 
perceived ease of use and perceived usefulness [9]. An 
analysis of the attitudes and perspectives of different health 
professionals was used to develop a checklist of 
organizational issues and challenges for implementation of 
telehealth projects [3]. A sociological approach has been 
used to develop the Normalization Process Theory, which 
looks at the impact of a new technology on patient-
professional relationships, inter-professional relationships, 
skills and training needs, and organizational goals [10]. 
Whilst such models describe useful frameworks in which to 
consider all the issues, they do not provide practical 
processes that developers can use effectively. 
The concept of co-design or co-innovation is one in 
which users are actively involved with developers from the 
planning and specification of a new product, through to 
completion [11]. Technology developers produce mock ups, 
storyboards, prototypes and other visual aids to enable users 
to understand what the new product might be and provide 
feedback at each stage. In theory the users help to design the 
product, by being actively engaged from the start and 
various tools have been developed to enable this to work 
effectively [12].  
In practice, it is difficult, as well as expensive, to make 
co-design work well. Users often struggle to understand the 
potential of new technology until they see a finished 
product. Furthermore, their availability is limited and it can 
be very hard to recruit an active user panel. In the case of 
telemedicine, the users may not even see themselves as 
users – they may not (yet) have the condition for which the 
solution is being developed. A study of a co-innovation  
approach to tele-rehabilitation for COPD patients [13]
identified several obstacles , including difficulties for the 
healthcare professionals viewing their patients as co-
innovators and inexperience in being creative about 
organizational design.  Again, co-design can end up by 
being another cost to the developer, without necessarily
producing sufficient benefits. 
IV. THE STAKEHOLDER EMPOWERED ADOPTION (SEA)
MODEL
The Stakeholder Empowered Adoption Model (SEA 
Model) has been developed to provide a framework that 
recognizes values of all the stakeholders and to propose a 
structured approach to incorporating them within the 
product design process [4].  Central to the process are two 
considerations. Firstly, each stakeholder type has a different 
set of values and perspectives through which they view 
evidence and make decisions. The key stages of design, 
evaluation and adoption-decision  need to take account of 
these values. Secondly, the transactional relationship 
between the healthcare commissioner and the technology 
provider must drive development. Both of these parties must 
take responsibility for the other stakeholders, who do not 
play an economic role in the transaction, but are key users. 
The four key stakeholder groups are the healthcare 
organization, the technology developer, the professional 
clinical staff and the patient (including family, friends, 
carers). In spite of very different perspectives and inter-
relationship, there is a common goal that all these groups 
share. If there is no common goal, the technology provider 
should not invest time in developing a solution. However, 
for telemedicine, we can generally summarise the shared 
goal as seeking to provide high quality clinical outcomes, 
but with greater convenience and efficiency. The inter-
relationships between the four are shown in Figure 1. The 
transactional relationship that must drive the process is the 
horizontal arrowed line, with the other relationships being 
less formal and shown by dotted vertical arrows.  
For the different groups of stakeholders, their criteria for 
a successful outcome from a telemedicine pilot will be 
different. For the ‘economic stakeholders’ (the healthcare 
organization and the technology developer) these are to do 
with financial and service effectiveness. For the ‘user 
stakeholders’ they may be more complex and sometimes 
related to entirely different factors than health itself (see 
Table I). 
To incorporate all these perspectives is, as many have 
already noted, a non-trivial task. The technology developer 
often feels that they are on the outside, trying to break in. 
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Fig. 1. The key stakeholder groups, their inter-relationships and 
perspectives for evaluating telemedicine innovations 
TABLE I. THE CRITERIA FOR SUCCESSFUL OUTCOMES OF A TELEMEDICINE 
PILOT, REFLECTING DIFFERENT VALUES AND PERSPECTIVES
Stakeholder group Values and outcomes
Technology provider x Workable and efficient system
x Scalable to a large market
Healthcare organization x Cost effective
x Clinically effective
Professional clinical 
staff
x Patient safety
x Improved clinical outcomes
x Minimal impact on work practices
Patients (including 
carers)
x Ease of use
x Rapid support if needed
x Minimal impact on daily lifestyle
The healthcare organization may eventually place a large 
and lucrative contract, but not until they have been able to 
demonstrate that their product will meet everyone’s needs. 
All this has to be done with very limited access to the busy 
healthcare professionals, who have their own operational 
targets that do not leave much time for what is to them ‘blue 
skies’ thinking. The patients and their carers may be more 
motivated to help to influence a new product, but they are 
not a coherent group and often find it difficult to be 
objective and generalize from their own personal, perhaps 
emotionally sensitive, experience. 
For the different groups of stakeholders, their criteria for 
a successful outcome from a telemedicine pilot will be 
different. For the ‘economic stakeholders’ (the healthcare 
organization and the technology developer) these are to do 
with financial and service effectiveness. For the ‘user 
stakeholders’ they may be more complex and related to 
entirely different factors than health itself. The SEA Model 
proposes a way for the economic stakeholders to work 
together from the outset and define an approach that enables 
the user stakeholders to engage at a level and time that is 
appropriate.  
The key principles for using the SEA Model in a product 
development process are as follows. The values of each user 
group need to be recognized and understood, in order to 
identify the common goal that justifies development to 
proceed. Each user group has limited time and is likely to 
find it hard to visualize what the technology has to offer. 
The technology developer needs to manage this process by 
planning very carefully how users are consulted and 
engaged, and by judicious use of prototypes and 
visualization tools. The economic relationship between the 
technology developer and the healthcare provider drives the 
process, but will be more successful if it is collaborative 
then adversarial.  
V. IMPLEMENTING THE STAKEHOLDER EMPOWERED 
ADOPTION MODEL
Implementation requires a different relationship between 
the transactional partners (economic stakeholders), with 
shared understanding from the start and a commitment to 
use an effective co-design methodology that takes account 
of the limited time availability of the user stakeholders.  
Ideas for new telemedicine apps come from many 
sources, but probably most frequently from a collaboration 
between a clinician or health professional and a technology 
developer. Often development may be grant funded, as may 
the piloting and evaluation phases. Only after this, do the 
commissioners get involved, at which point they are seeking 
to procure finished solutions, ideally complete with the 
associated healthcare delivery pathway.  
For telemedicine solutions to be adopted, the healthcare 
delivery pathway and the technology need to be designed 
together, and patient/carer input needs to be fully researched 
to aid development of both. This requires a completely 
different way of doing product development and user 
evaluation. Essentially, given the high costs of development, 
it means finding a way to engage in healthcare delivery 
design using prototypes.  
One of the concepts emerging in the telemedicine debate 
is that of patient empowerment. The traditional clinician-
patient relationship is changing, to one where the patient 
expects to have more information and knowledge of their 
condition, the options for treatment, risks and benefits and 
then to have a share in the decision of which is the best 
option. This is a radical change that requires re-education of 
both the patient and the health professional. It also requires a 
change to how health services are delivered.  
A recent study explored barriers to adoption of 
telemonitoring within the UK Whole System 
Demonstrator [2] noted fears from patients that they would 
lose the current support provided to them, rather than seeing 
the technological support as something additional and 
beneficial. Many concerns were also voiced relating to 
difficulties engaging with technology, privacy and data 
security, but the issues around the care relationship are 
something rather different that have not yet been addressed 
by the technical community. Both developers and health 
commissioners need to recognize that telemedicine is 
potentially a paradigm shift in how care is delivered. 
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Telemedicine enables patients to be empowered and to self 
manage their condition. This changes the patient-clinician 
relationship and requires a re-education by both parties. 
Hence the developers and health commissioners have a 
more significant task to undertake than simply a 
procurement and sales process. They need to work closely to 
build this new type of health delivery. By changing from an 
adversarial, transactional relationship to one that is 
consultative and developmental, the views of the other 
stakeholders (patients and health professionals) can be 
properly incorporated. 
So what can a technology developer do to influence 
health commissioners and the adoption process? Engaging 
with users and stakeholders earlier in the process of 
development must be a key aim. The SEA Model proposes a 
structured process in which the first step is to understand the 
commissioning objectives (for example, reduce emergency 
admissions for patients with long term conditions such as 
diabetes or COPD due to poor management of their 
condition). The idea then needs to be developed and 
explained just in enough detail to get the interest of 
commissioners and health professionals, so that they can 
begin to engage and understand the implications for service 
delivery. The process should continue iteratively, using 
progressively more and more sophisticated prototypes, to 
involve other types of users with the support of the 
commissioners (see Figure 2). 
The technology developer needs to use their connections 
with health professionals very carefully. Clinicians and 
other professionals (nurses, social workers, occupational 
therapists etc) may have some influence in the decision 
making process, but will certainly have knowledge and 
insights that can guide the developer in understanding how 
their innovation is going to impact on delivery. However, 
there are often negative perceptions of telemedicine, 
because of its impact on job roles and routines. At worst, 
health professionals fear being ‘superseded by a computer’, 
at best, they are right to assume some changes to their work 
routine. The technology developer needs to recognize these 
concerns and to turn them to a positive by harnessing their 
very detailed knowledge of processes and patient 
experiences.  
Recent growth of interest in the patient voice within 
healthcare delivery is helpful to the developer, as there are 
now many networks and charitable initiatives to support 
‘expert patients’, often according to particular illnesses and 
conditions. The contributions of these groups can be highly 
beneficial to any product design process, but needs to be 
carefully managed and handled as part of an overall picture. 
Patients (and their carers) see a relatively narrow view of the 
healthcare experience. This issue can be handled by a 
process of cross-checking with other users, especially health 
professionals. However, in order to be most useful, the 
involvement of patients and carers needs to be structured so 
that they are able to provide input in a way that is 
convenient to them, occurs frequently from an early stage of 
development through to the evaluation stage and provides 
them with sufficient information and visualization tools to 
be useful.  
The use of social online media to allow different groups 
to contribute as a product develops is attractive. Through 
providing visual concepts online, developers can allow 
different stakeholders to contribute feedback more 
conveniently. Developers can also make use of online 
groups such as the Patients Like Me network [14], which 
provides rich information on particular conditions and from 
where patients can be recruited to studies.  
The model is currently an idealized process and we are 
working with technology companies, commissioners and 
health professionals to find suitable test cases. 
Fig.2. An idealized process for stakeholder engagement throughout the 
product development process. 
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